Nexalis Therapeutics Limited · ASX:NX1
Nexalis Therapeutics — Investor Presentation (2026)
16 slides from Nexalis Therapeutics's investor presentation, 2026
Slide 1: Clinical Development Outlook 2026
Developing the next generation of pain management & mental health therapies Clinical Development Outlook 2026
Slide 2: Disclaimer
Disclaimer This presentation contains summary information about InhaleRx Limited This presentation may contain forward-looking statements including (“InhaleRx” or “IRX” or “Company”) and its activities current as at the date of this statements regarding our intent, belief or current expectations wit
Slide 3: Rebrand to Nexalis Therapeutics (ASX:NX1)
Rebrand to Nexalis Therapeutics (ASX:NX1) The Company is currently rebranding for reclassification purposes and to accommodate the new oral asset, given the Company no longer only specialises in inhaled delivery. Nexalis Therapeutics (ASX:NX1) website is complete, all digital assets are templated an
Slide 4: Company Snapshot
Company Snapshot Nexalis Therapeutics (ASX:NX1) is developing the next generation of pain management & mental health therapies by addressing unmet and mismatched medical needs of patients globally. Three drug candidates SRX-25 – new oral therapy added to HREC Approved and manufacturing in developmen
Slide 5: SRX-25 – Oral Drug Therapeutic targeting Treatment-Resistant Depression (TRD)
SRX-25 – Oral Drug Therapeutic targeting Treatment-Resistant Depression (TRD) SRX-25 has SRX-25 is designed Development Fully funded clinical Value creation potential to provide an to replicate Spravato’s via 505(b)(2) regulatory development plans opportunities via alternative to pharmacokinetics wh
Slide 6: SRX-25 Commercial Opportunity – TRD
SRX-25 Commercial Opportunity – TRD 1 2.8 million TRD patients in the US alone 2 U.S. currently makes up over 50% of the global TRD market1 SRX-25 COMMERCIAL OPPORTUNITY 3 Significant demand for a more accessible and tolerable form of esketamine therapy2 $4b USD 4 Regulatory pathway defined by app
Slide 7: The Rise of Ketamine as a Pharmaceutical – The Blockbuster Opportunity
The Rise of Ketamine as a Pharmaceutical – The Blockbuster Opportunity 7
Slide 8: IRX-211 – Inhaled Drug / Device Therapeutic targeting BTcP
IRX-211 – Inhaled Drug / Device Therapeutic targeting BTcP IRX-211 will be a registered prescription-only medication to treat Breakthrough Cancer Pain (BTcP). Ph1 clinical trial complete – very promising insights and no SAE’s. Ph2 approved by HREC, manufacturing complete and site activated to start
Slide 9: IRX-211 – Commercial Opportunity
IRX-211 – Commercial Opportunity 1 By 2040, the global cancer burden is projected to reach approximately 29.5 million new cases annually. 20%-40% U.S. cancer patients reporting cannabis use to 2 help treat their condition IRX-211 COMMERCIAL OPPORTUNITY Growing demand / widening gap in the market 3
Slide 10: Planning to commence IRX-211
Planning to commence IRX-211 MILESTONE COMPLETE EXPECTED (QUARTER) Funding Secured CRO appointed Spec Work Completed in UK Component Sourcing + Tech Transfer HREC Approval for Ph2 trial Protocol Amendment with HREC Approved Batch Manufacturing Complete Site Activated and Site Staff Trained First Pat
Slide 11: IRX-616a – Inhaled Drug / Device Therapeutic targeting Panic Disorder
IRX-616a – Inhaled Drug / Device Therapeutic targeting Panic Disorder IRX-616a will be HREC approved, Regulatory Patent attorneys No competition in Access to a registered this trial will be approval(s) with engaged to pursue terms of inhaled government prescription-only promptly the FDA will allow a
Slide 12: IRX-616a – Commercial Opportunity
IRX-616a – Commercial Opportunity 1 There are currently no FDA approved drugs for treating Panic Disorder via inhalation. 2 Covid-19 triggered a 25% increase in prevalence, median onset age of 24. IRX-616a COMMERCIAL OPPORTUNITY 3 Existing drugs like SSRI’s can affect sleep, sexual function, carry d
Slide 13: Planning to commence IRX-616a
Planning to commence IRX-616a MILESTONE COMPLETE EXPECTED (QUARTER) Funding Secured Medical writing complete Spec Work Completed in UK Component Sourcing + Tech Transfer Completed CRO appointed HREC Application HREC Approval Batch Manufacturing Site CTRA Executed and SIV Complete First Patient Scree
Slide 14: Pipeline – Three Assets Under Development
Pipeline – Three Assets Under Development Drug Indication Planning Phase 1 Phase 2 Funded Value Breakthrough IRX-211 $15.5m cancer pain IRX-616a Panic disorder $16.1m Treatment-resistant SRX-25 $12.6m depression All three programs are fully funded for clinical development costs amount to over $50m u
Slide 15: Summary of Outlook for 2026
Summary of Outlook for 2026 Unique funding Two HREC Approvals Excellent and Fantastic IRX-616a has a Ph1 all position with over secured with both trials unprecedented opportunity with planned out with $50m secured for ready to commence. positioning with IRX-211. SRX-25 in a proven CMAX. the intent o
Slide 16: Thank you
Thank you Darryl Davies CEO darryl.davies@inhalerx.com.au